MicroRNAs serve as potential blood biomarkers for COVID-19 severity in cancer patients
Immunocompromised cancer patients who are infected by SARS-CoV-2 are at risk of developing severe COVID-19 with potentially fatal complications. Biomarkers capable of predicting those most at risk could help physicians better treat these patients. Researchers led by Simone Anfossi, Ph.D., and George Calin, M.D., Ph.D., identified several microRNAs – small non-coding RNA molecules – located close to genomic regions associated with the severity and susceptibility of COVID-19. The researchers analyzed plasma samples from 128 cancer patients infected...